Mesoblast (MESO) EBT Growth (3y) (2017 - 2023)
Powered by 
Analysis
Mesoblast (MESO) EBT Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 103.79% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.03% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 41.79% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 38.36% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.56% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 64.03% |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 28.72% |
| Dec 31, 2022 | 10.51% |
| Sep 30, 2022 | -31.70% |
| Jun 30, 2022 | 106.17% |
| Mar 31, 2022 | 7.73% |
| Dec 31, 2021 | 1.78% |
| Sep 30, 2021 | -3.96% |
| Jun 30, 2021 | 116.19% |
| Mar 31, 2021 | -2.71% |
| Dec 31, 2020 | -38.52% |
| Sep 30, 2020 | -36.58% |
| Mar 31, 2020 | -58.72% |
| Dec 31, 2019 | -13.92% |
| Sep 30, 2019 | 31.33% |
| Jun 30, 2019 | 11.27% |
| Mar 31, 2019 | -21.21% |
| Dec 31, 2018 | -7.16% |
| Sep 30, 2018 | -28.31% |
| Jun 30, 2018 | 10.59% |
| Mar 31, 2018 | -11.92% |